(CercleFinance.com) – AstraZeneca reports that its Enhertu, co-developed with Daiichi Sankyo, has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with previously treated HER2-positive advanced gastric cancer.
The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) in November 2022 and is based on the results of the phase II trials DESTINY-Gastric02 and DESTINY-Gastric01.
Around 136,000 cases of gastric cancer are diagnosed each year in Europe, where it is the sixth leading cause of cancer death. It is usually diagnosed at an advanced stage and about one in five gastric cancers are HER2-positive.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
